M Sterneck1, U Settmacher2, T Ganten3, C Sarrazin4, N Speidel5, D Broering6, N Heyne7, E Paulus8, M Mertens8, L Fischer9. 1. Universitätsklinikum, Hamburg-Eppendorf, Hamburg, Germany. Electronic address: sterneck@uke.de. 2. Universitätsklinikum Jena, Lobeda, Jena, Germany. 3. Universitätsklinikum Heidelberg, Heidelberg, Germany. 4. (d)Klinikum Joh.Wolfg.Goethe-UNI Zentrum d.Inneren Medizin Medizinische Klinik I, Frankfurt, Hessen, Deutschland, Germany. 5. (e)Universitätsklinikum Bonn (AöR), Bonn, Germany. 6. Klinik für Allgemeine Chirurgie und Thoraxchirurgie, Kiel, Germany. 7. Universitätsklinikum Tübingen, Medizinische Klinik IV, Sektion Nieren- und Hochdruckkrankheiten, Tübingen, Germany. 8. Stefan Scheidl, Novartis Pharma GmbH, Nuernberg, Germany. 9. Universitätsklinikum, Hamburg-Eppendorf, 20246 Hamburg, Germany.
Abstract
OBJECTIVE: To evaluate improvement in gastrointestinal (GI) symptoms and health-related quality of life (HRQoL) in liver transplant recipients switched from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS). METHODS: A multicenter, open-label, single-arm study was undertaken in maintenance liver transplant recipients who reported GI complications with MMF therapy. The patients were switched to equimolar doses of EC-MPS at baseline. The primary end point was the change in the Gastrointestinal Symptom Rating Scale (GSRS) total score after 6 to 8 weeks of treatment with EC-MPS. Other key assessments for GI symptoms and HRQoL included the GSRS subscores, the Gastrointestinal Quality of Life Index (GIQLI), the Psychological General Well-Being Index, and the Overall Treatment Effect (OTE). Paired t-test was used to assess the difference in the mean score changes over time. RESULTS: A total of 34 patients were enrolled and switched to equimolar doses of EC-MPS. After 6 to 8 weeks of EC-MPS treatment, mean GSRS total score improved significantly from 2.88 ± 0.66 to 2.10 ± 0.78. Mean improvement in GSRS total score (-0.77 score points; P = .001) exceeded the minimal clinically important difference. Significant improvements were observed in all GSRS subscales (P < .05), GIQLI total scores (P = .001), and GIQLI subscales "GI symptoms" (P < .001) and "physical function" (0.013). Patients who continued EC-MPS reported sustained benefits compared with patients who switched back to MMF after 6 to 8 weeks of treatment with EC-MPS. On the OTE scale, improvement in symptoms was reported in 76.5% and 61.8% of the patients as perceived by the physicians and the patients. Improvement in HRQoL was reported by 41.2% of the patients. No deaths, biopsy proven acute rejections, or graft losses were reported during the study. CONCLUSION: Conversion from MMF to EC-MPS was associated with a significant improvement in GI symptoms and HRQoL in liver transplant recipients.
OBJECTIVE: To evaluate improvement in gastrointestinal (GI) symptoms and health-related quality of life (HRQoL) in liver transplant recipients switched from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS). METHODS: A multicenter, open-label, single-arm study was undertaken in maintenance liver transplant recipients who reported GI complications with MMF therapy. The patients were switched to equimolar doses of EC-MPS at baseline. The primary end point was the change in the Gastrointestinal Symptom Rating Scale (GSRS) total score after 6 to 8 weeks of treatment with EC-MPS. Other key assessments for GI symptoms and HRQoL included the GSRS subscores, the Gastrointestinal Quality of Life Index (GIQLI), the Psychological General Well-Being Index, and the Overall Treatment Effect (OTE). Paired t-test was used to assess the difference in the mean score changes over time. RESULTS: A total of 34 patients were enrolled and switched to equimolar doses of EC-MPS. After 6 to 8 weeks of EC-MPS treatment, mean GSRS total score improved significantly from 2.88 ± 0.66 to 2.10 ± 0.78. Mean improvement in GSRS total score (-0.77 score points; P = .001) exceeded the minimal clinically important difference. Significant improvements were observed in all GSRS subscales (P < .05), GIQLI total scores (P = .001), and GIQLI subscales "GI symptoms" (P < .001) and "physical function" (0.013). Patients who continued EC-MPS reported sustained benefits compared with patients who switched back to MMF after 6 to 8 weeks of treatment with EC-MPS. On the OTE scale, improvement in symptoms was reported in 76.5% and 61.8% of the patients as perceived by the physicians and the patients. Improvement in HRQoL was reported by 41.2% of the patients. No deaths, biopsy proven acute rejections, or graft losses were reported during the study. CONCLUSION: Conversion from MMF to EC-MPS was associated with a significant improvement in GI symptoms and HRQoL in liver transplant recipients.
Authors: Faisal A Abaalkhail; Mohammed I Al Sebayel; Mohammed A Shagrani; Wael A O'Hali; Nasser M Almasri; Abduljaleel A Alalwan; Mohammed Y Alghamdi; Hamad Al-Bahili; Mohammed S AlQahtani; Saleh I Alabbad; Waleed K Al-Hamoudi; Saleh A Alqahtani Journal: Saudi Med J Date: 2021-09 Impact factor: 1.422
Authors: Raphael Schiffmann; Daniel G Bichet; Ana Jovanovic; Derralynn A Hughes; Roberto Giugliani; Ulla Feldt-Rasmussen; Suma P Shankar; Laura Barisoni; Robert B Colvin; J Charles Jennette; Fred Holdbrook; Andrew Mulberg; Jeffrey P Castelli; Nina Skuban; Jay A Barth; Kathleen Nicholls Journal: Orphanet J Rare Dis Date: 2018-04-27 Impact factor: 4.123
Authors: Dominique P Germain; Kathy Nicholls; Roberto Giugliani; Daniel G Bichet; Derralynn A Hughes; Laura M Barisoni; Robert B Colvin; J Charles Jennette; Nina Skuban; Jeffrey P Castelli; Elfrida Benjamin; Jay A Barth; Christopher Viereck Journal: Genet Med Date: 2019-02-06 Impact factor: 8.822
Authors: Zakiyah Kadry; Jonathan G Stine; Takehiko Dohi; Ashokkumar Jain; Kimberly L Robyak; Osun Kwon; Christopher J Hamilton; Piotr Janicki; Thomas R Riley; Fauzia Butt; Karen Krok; Ian R Schreibman; Dmitri Bezinover; Nasrollah Ghahramani; Stalin Campos; Christopher S Hollenbeak Journal: Transplant Direct Date: 2021-06-08